• 1
    Khosla S. Update in male osteoporosis. J Clin Endocrinol Metab. 2010; 95(1):310.
  • 2
    Seeman E. Pathogenesis of bone fragility in women and men. Lancet. 2002; 359:184150.
  • 3
    Compston J. Secondary causes of osteoporosis in men. Calcif Tissue Int. 2001; 69(4):1935.
  • 4
    Olszynski WP, Shawn Davison K, Adachi JD, Brown JP, Cummings SR, Hanley DA, Harris SP, Hodsman AB, Kendler D, McClung MR, Miller PD, Yuen CK. Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment. Clin Ther. 2004; 26(1):1528.
  • 5
    Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich GA. The effect of teriparatide (human parathyroid hormone (1-34)) therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003; 18:917.
  • 6
    Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P, Weinstein RS. Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res. 2010; 25(10):223950.
  • 7
    Ringe JD, Faber H, Dorst A. Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocrinol Metab. 2001; 86(11):52525.
  • 8
    Ho YY, Fraumann AG, Thomson W, Seeman E. Effects of alendronate on bone density in men with primary and secondary osteoporosis. Osteoporos Int. 2001; 11(2):98101.
  • 9
    Sambrook PN, Roux C, Devogelaer JP, Saag K, Lau CS, Reginster JY, Bucci-Rechtweg C, Su G, Reid DM. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate. Bone. 2012; 50(1):28995. Erratum in: Bone. 2012 Mar;50(3):811.
  • 10
    Lamy O, Sandini L, Pache I, Fatio S, Burnand J, Burckhardt P. Intravenous ibandronate in men with osteoporosis: an open pilot study over 2 years. J Endocrinol Invest. 2003; 26:72832.
  • 11
    Ringe JD, Dorst A, Farahmand P. Efficacy of strontium ranelate on bone mineral density in men with osteoporosis. Arzneimittelforschung. 2010; 60(5):26772.
  • 12
    Orwoll ES, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000; 86:52525.
  • 13
    Reid M, Adami S, Devogelaer JP, Chines AA. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int. 2001; 69(4):2427.
  • 14
    Sato Y, Iwamoto J, Kanoko T, Satoh K. Risedronate sodium therapy for prevention of hip fractures in men 65 years or older after stroke. Arch Intern Med. 2005; 165(15):17438.
  • 15
    Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J, Langdahl B, Rizzoli R, Lipschitz S, Dimai HP, Witvrouw R, Eriksen E, Brixen K, Russo L, Claessens F, Papanastasiou P, Antunez O, Su G, Bucci-Rechtweg C, Hruska J, Incera E, Vanderschueren D, Orwoll E. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med. 2012; 367(18):171423.
  • 16
    Weiner S, Wagner HD. The material bone: structure–function relations. Annu Rev Mater Sci. 1998; 28:27198.
  • 17
    Fratzl P, Gupta H, Paschalis E, Roschger P. Structure and mechanical quality of the collagen-mineral nano-composite in bone. J Material Chem. 2004; 14:211523.
  • 18
    Seeman E, Delmas PD. Bone quality—the material and structural basis of bone strength and fragility. N Engl J Med. 2006; 354:225061.
  • 19
    Roschger P, Gupta HS, Berzlanovich A, Ittner G, Dempster DW, Fratzl P, Cosman F, Parisien M, Lindsay R, Nieves JW, Klaushofer K. Constant mineralization density distribution in cancellous human bone. Bone. 2003; 32:31623.
  • 20
    Roschger P, Paschalis EP, Fratzl P, Klaushofer K. Bone mineralization density distribution in health and disease. Bone. 2008; 42:45666.
  • 21
    Genant HK. Assessment of vertebral fractures in osteoporosis research. J Rheumatol. 1997; 24:12124.
  • 22
    Smith-Bindman R, Cummings SR, Steiger P, Genant HK. A comparison of morphometric definitions of vertebral fracture. J Bone Miner Res. 1991; 6:2534.
  • 23
    Genant HK, Jergas M, Palermo L, Nevitt M, Valentin RS, Black D, Cummings SR. Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res. 1996; 11:98496.
  • 24
    Patsch JM, Kohler T, Berzlanovich A, Muschitz C, Bieglmayr C, Roschger P, Resch H, Pietschmann P. Trabecular bone microstructure and local gene expression in iliac crest biopsies of men with idiopathic osteoporosis. J Bone Miner Res. 2011; 26:158492.
  • 25
    Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987; 2:595610.
  • 26
    Rehman MT, Hoyland JA, Denton J, Freemont AJ. Age related histomorphometric changes in bone in normal British men and women. J Clin Pathol. 1994; 47(6):52934.
  • 27
    Roschger P, Fratzl P, Eschberger J, Klaushofer K. Validation of quantitative backscattered electron imaging for the measurement of mineral density distribution in human bone biopsies. Bone. 1998; 23:31926.
  • 28
    Fratzl P, Roschger P, Fratzl-Zelman N, Paschalis EP, Phipps R, Klaushofer K. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume. Calcif Tissue Int. 2007; 81:7380.
  • 29
    Zizak I, Roschger P, Paris O, Misof BM, Berzlanovich A, Bernstorff S, Amenitsch H, Klaushofer K, Fratzl P. Characteristics of mineral particles in the human bone/cartilage interface. J Struct Biol. 2003; 141:20817.
  • 30
    Gong JK, Arnold JS, Cohn SH. The density of organic and volatile and non-volatile inorganic components of bone. Anat Rec. 1964; 149:31924.
  • 31
    Ostertag A, Cohen-Solal M, Audran M, Legrand E, Marty C, Chappard D, de Vernejoul MC. Vertebral fractures are associated with increased cortical porosity in iliac crest bone biopsy of men with idiopathic osteoporosis. Bone. 2009; 44(3):4137.
  • 32
    Ciria-Recasens M, Perez-Edo L, Blanch-Rubio J, Marinoso ML, Benito-Ruiz P, Serrano S, Carbonell-Abello J. Bone histomorphometry in 22 male patients with normocalciuric idiopathic osteoporosis. Bone. 2005; 36:92630.
  • 33
    Pernow Y, Granberg B, Saaf M, Weidenhielm L. Osteoblast dysfunction in male idiopathic osteoporosis. Calcif Tissue Int. 2006; 78:907.
  • 34
    Pernow Y, Hauge EM, Linder K, Dahl E, Sääf M. Bone histomorphometry in male idiopathic osteoporosis. Calcif Tissue Int. 2009; 84(6):4308.
  • 35
    Ruiz-Gaspa S, Blanch-Rubio J, Ciria-Recasens M, Monfort J, Tio L, Garcia-Giralt N, Nogues X, Monllau JC, Carbonell-Abello J, Perez-Edo L. Reduced proliferation and osteocalcin expression in osteoblasts of male idiopathic osteoporosis. Calcif Tissue Int. 2010; 86:2202.
  • 36
    Khosla S. Idiopathic osteoporosis: is the osteoblast to blame? J Clin Endocrinol Metab. 1997; 82:27924.
  • 37
    Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone. 2000; 27:68794.
  • 38
    Roschger P, Rinnerthaler S, Yates J, Rodan GA, Fratzl P, Klaushofer K. Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone. 2001; 29(2):18591.
  • 39
    Boivin G, Meunier PJ. Effects of bisphosphonates on matrix mineralization. J Musculoskelet Neuronal Interact. 2002; 2:53843.
  • 40
    Zoehrer R, Roschger P, Fratzl P, Durchschlag E, Paschalis E, Phipps R, Klaushofer K. Effects of 3- and 5-year treatment with Risedronate on the bone mineral density distribution of cancellous bone in human iliac crest biopsies. J Bone Miner Res. 2006; 21:110612.
  • 41
    Fratzl-Zelman N, Roschger P, Misof BM, Nawrot-Wawrzyniak K, Pötter-Lang S, Muschitz C, Resch H, Klaushofer K, Zwettler E. Fragility fractures in men with idiopathic osteoporosis are associated with undermineralization of the bone matrix without evidence of increased bone turnover. Calcif Tissue Int. 2011; 88(5):37887.
  • 42
    Misof B, Gamsjaeger S, Cohen A, Hofstetter B, Roschger P, Stein E, Nickolas T, Rogers H, Dempster D, Zhou H, Recker R, Lappe J, McMahon D, Paschalis E, Fratzl P, Shane E, Klaushofer K. Bone material properties in premenopausal women with idiopathic osteoporosis. J Bone Miner Res. 2012; 27(12):255161.
  • 43
    Boivin G, Bala Y, Doublier A, Farlay D, Ste-Marie LG, Meunier PJ, Delmas PD. The role of mineralization and organic matrix in the microhardness of bone tissue from controls and osteoporotic patients. Bone. 2008; 43(3):5328.
  • 44
    Ruffoni D, Fratzl P, Roschger P, Klaushofer K, Weinkamer R. The bone mineralization density distribution as a fingerprint of the mineralization process. Bone. 2007; 40:130819.
  • 45
    Recker R, Lappe J, Davies KM, Heaney R. Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients. J Bone Miner Res. 2004; 19:162833.
  • 46
    Borah B, Dufresne TE, Ritman EL, Jorgensen SM, Liu S, Chmielewski PA, Phipps RJ, Zhou X, Sibonga JD, Turner RT. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. Bone. 2006; 39:34552.
  • 47
    Misof BM, Roschger P, Gabriel D, Paschalis EP, Eriksen EF, Recker RR, Gasser JA, Klaushofer K. Annual intravenous zoledronic acid for three years increased cancellous bone matrix mineralization beyond normal values in the HORIZON biopsy cohort. J Bone Miner Res. 2013; 28(3):4428.
  • 48
    Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356(18):180922.
  • 49
    Misof BM, Bodingbauer M, Roschger P, Wekerle T, Pakrah B, Haas M, Kainz A, Oberbauer R, Mühlbacher F, Klaushofer K. Short-term effects of high-dose zoledronic acid treatment on bone mineralization density distribution after orthotopic liver transplantation. Calcif Tissue Int. 2008; 83:16775.
  • 50
    Borah B, Dufresne T, Nurre J, Phipps R, Chmielewski P, Wagner L, Lundy M, Bouxsein M, Zebaze R, Seeman E. Risedronate reduces intracortical porosity in women with osteoporosis. J Bone Miner Res. 2010; 25(1):417.
  • 51
    Parisien MV, McMahon D, Pushparaj N, Dempster DW. Trabecular architecture in iliac crest bone biopsies: infra-individual variability in structural parameters and changes with age. Bone. 1988; 9(5):28995.
  • 52
    Kingsmill VJ, Gray CM, Moles DR, Boyde A. Cortical vascular canals in human mandible and other bones. J Dent Res. 2007; 86(4):36872.
  • 53
    Liberman UA, Hochberg MC, Geusens P, Shah A, Lin J, Chattopadhyay A, Ross PD. Hip and non-spine fracture risk reductions differ among antiresorptive agents: evidence from randomised controlled trials. Int J Clin Pract. 2006; 60(11):1394400.
  • 54
    Genant HK, Lewiecki EM, Fuerst T, Fries M. Effect of monthly ibandronate on hip structural geometry in men with low bone density. Osteoporos Int. 2012; 23(1):25765.
  • 55
    Nakamura T, Nakano T, Ito M, Hagino H, Hashimoto J, Tobinai M, Mizunuma H. Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis. Calcif Tissue Int. 2013; 93(2):13746.
  • 56
    Zebaze RM, Ghasem-Zadeh A, Bohte A, Iuliano-Burns S, Mirams M, Price RI, Mackie EJ, Seeman E. Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet. 2010; 375(9727):172936.